Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

688 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dermatologic adverse events associated with targeted therapies for melanoma.
Scarpato L, Festino L, Vanella V, Madonna G, Mastroianni M, Palla M, Ascierto PA. Scarpato L, et al. Among authors: ascierto pa. Expert Opin Drug Saf. 2022 Mar;21(3):385-395. doi: 10.1080/14740338.2022.1986000. Epub 2021 Nov 2. Expert Opin Drug Saf. 2022. PMID: 34595993
Main roads to melanoma.
Palmieri G, Capone M, Ascierto ML, Gentilcore G, Stroncek DF, Casula M, Sini MC, Palla M, Mozzillo N, Ascierto PA. Palmieri G, et al. Among authors: ascierto ml, ascierto pa. J Transl Med. 2009 Oct 14;7:86. doi: 10.1186/1479-5876-7-86. J Transl Med. 2009. PMID: 19828018 Free PMC article. Review.
The role of spectrophotometry in the diagnosis of melanoma.
Ascierto PA, Palla M, Ayala F, De Michele I, Caracò C, Daponte A, Simeone E, Mori S, Del Giudice M, Satriano RA, Vozza A, Palmieri G, Mozzillo N. Ascierto PA, et al. BMC Dermatol. 2010 Aug 13;10:5. doi: 10.1186/1471-5945-10-5. BMC Dermatol. 2010. PMID: 20707921 Free PMC article. Clinical Trial.
NF-κB as potential target in the treatment of melanoma.
Madonna G, Ullman CD, Gentilcore G, Palmieri G, Ascierto PA. Madonna G, et al. Among authors: ascierto pa. J Transl Med. 2012 Mar 20;10:53. doi: 10.1186/1479-5876-10-53. J Transl Med. 2012. PMID: 22433222 Free PMC article. Review.
The role of BRAF V600 mutation in melanoma.
Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, Palmieri G, Testori A, Marincola FM, Mozzillo N. Ascierto PA, et al. J Transl Med. 2012 Jul 9;10:85. doi: 10.1186/1479-5876-10-85. J Transl Med. 2012. PMID: 22554099 Free PMC article.
Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma.
Daponte A, Signoriello S, Maiorino L, Massidda B, Simeone E, Grimaldi AM, Caracò C, Palmieri G, Cossu A, Botti G, Petrillo A, Lastoria S, Cavalcanti E, Aprea P, Mozzillo N, Gallo C, Comella G, Ascierto PA; Southern Italy Cooperative Oncology Group (SICOG). Daponte A, et al. Among authors: ascierto pa. J Transl Med. 2013 Feb 13;11:38. doi: 10.1186/1479-5876-11-38. J Transl Med. 2013. PMID: 23402397 Free PMC article. Clinical Trial.
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zubel A, Dummer R. Ascierto PA, et al. Lancet Oncol. 2013 Mar;14(3):249-56. doi: 10.1016/S1470-2045(13)70024-X. Epub 2013 Feb 13. Lancet Oncol. 2013. PMID: 23414587 Clinical Trial.
The role of optical radiations in skin cancer.
Ayala F, Palla M, Di Trolio R, Mozzillo N, Ascierto PA. Ayala F, et al. Among authors: ascierto pa. ISRN Dermatol. 2013 Apr 24;2013:842359. doi: 10.1155/2013/842359. Print 2013. ISRN Dermatol. 2013. PMID: 23710365 Free PMC article.
688 results